| |||||||
Creutzfeldt-Jakob Disease |
![]() |
| Creutzfeldt-Jakob Disease (CJD) is a rare form of progressive dementia characterized by degeneration and loss of nerve cells leading to the production of microscopic holes in the brain. How does Creutzfeldt-Jakob Disease affect the person?CJD usually has rapid onset and decline. Early symptoms may include lapses in memory, mood swings similar to depression, lack of interest and social withdrawal. The person may become unsteady on his/her feet. Later symptoms may include blurred vision, sudden jerking movements and rigidity in the limbs. The person may experience slurred speech and have difficulty swallowing. Eventually, movement and speech are lost. Who gets Creutzfeldt-Jakob Disease?Both men and women can be affected by CJD. The usual age of onset is 45-75 years. In Canada, all cases of CJD are reported to the National CJD Surveillance Unit in Ottawa, which has been gathering information on the disease since 1997. What are the types of Creutzfeldt-Jakob Disease?There are four forms of the disease:
How is Creutzfeldt-Jakob Disease transmitted?CJD is unique because it can be inherited or transmitted. The infectious agent is believed to be an abnormal form of the prion protein (PrP). However, CJD is not infectious in the usual way -- like colds or flu, or by skin contact. It is transmitted only through contact with, or dietary exposure to, CJD brain matter. There are no special risks in caring for a person with CJD. The agent has been compared to a "slow virus" because there is a long incubation period (1-30 years) before signs of the disease appear. Once symptoms are visible, decline is usually rapid. Depending upon the type of CJD, the length of the illness is usually a year but can range from months to several years after onset. Is there a treatment for Creutzfeldt-Jakob Disease?Currently, there is no way to slow the progression of the disease. Some medications can help relieve jerking movements and unsteadiness. For more information:
(1) Canadian Statistics and Incidence of CJD Cases: www.phac-aspc.gc.ca/hcai-iamss/cjdss-ssmcj/stats_ehtml#canada. The contents of this document are provided for information purposes only, and do not represent advice, an endorsement or a recommendation, with respect to any product, service or enterprise, and/or the claims and properties thereof, by the Alzheimer Society of Canada. The Information Sheet is not intended to replace clinical diagnosis by a health professional. Source: May 2005 - Research-
Related Dementia - Creutzfeldt-Jakob Disease - Alzheimer Society of Canada. |
|
Contact us: write@dementiatoronto.org |
||